What is Mupirocin and What is it Used For?
Mupirocin is an antibiotic used to treat bacterial skin infections [1]. It is a topical medication, meaning it is applied directly to the skin [2]. Common infections treated with mupirocin include impetigo, a contagious skin infection, and the prevention of infection in minor skin abrasions [1].
When Will Mupirocin Patents Expire?
The patent landscape for mupirocin varies depending on the specific formulation and its intended use. DrugPatentWatch.com tracks patent expiry dates for pharmaceuticals, offering detailed information on these timelines [3]. Generally, many of the foundational patents for mupirocin have expired, opening the door for generic versions [3].
Can Generic Mupirocin Be Available in 2026?
The availability of generic mupirocin in 2026 is likely, as many primary patents have already expired [3]. Generic drug approval processes, however, involve demonstrating bioequivalence to the brand-name drug, which can take time. The exact timing can depend on regulatory reviews and any remaining patent protections for specific formulations or delivery methods.
Who Makes Mupirocin and Are There Competitors?
Mupirocin is manufactured by various pharmaceutical companies under different brand names and as generics [1]. Competitors in the topical antibiotic market include other agents used for similar skin infections, such as bacitracin, neomycin, and polymyxin B, often found in combination products [4].
What are the Risks or Side Effects of Mupirocin?
The most common side effects of topical mupirocin include local reactions at the application site, such as burning, stinging, itching, redness, or dryness [1]. Systemic absorption is minimal, reducing the risk of widespread side effects. However, allergic reactions are possible, though rare [1].
How Does Mupirocin Work?
Mupirocin works by inhibiting bacterial protein synthesis [1]. It targets a specific enzyme, isoleucyl-tRNA synthetase, which is essential for bacteria to build proteins necessary for their survival and growth [5]. This mechanism is specific to bacterial ribosomes, minimizing effects on human cells.